Here is My Question:
Is there an increased risk of relapse after stopping Rituxan the way there is with Tysabri? Second, does Rituxan preclude patients from taking other drugs such as Tecfidera or even Tysabri and others in the future? Third, does the JCV+ antibody test done with Tysabri also mean a person has that same risk of PML with Rituxan?
These are all very good questions for which we currently have only partial answers.
All of these answers must be tempered with some degree of caution as there here have been limited controlled studies of rituximab treatment in MS patients . For the time being these are the best answers that I can provide based on the evidence available.
Rip Kinkel, MD
PLEASE NOTE: The information/opinions on this site should be used as an information resource only. This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.